Phase II Study
Cohort A (32 patients): Adult patients with relapsed/refractory (RR) stage II-IV mantle cell lymphoma (MCL) after at least one line of previous treatment who have not previously been exposed to Bruton tyrosine kinase inhibitors (BTKi)
Cohort B (64 patients): Adult patients with treatment naïve (TN) stage II-IV MCL unsuitable for an intensive, cytarabine and platinum-based induction treatment regimen.
Phase II Study
Cohort A (32 patients): Adult patients with relapsed/refractory (RR) stage II-IV mantle cell lymphoma (MCL) after at least one line of previous treatment who have not previously been exposed to Bruton tyrosine kinase inhibitors (BTKi)
Cohort B (64 patients): Adult patients with treatment naïve (TN) stage II-IV MCL unsuitable for an intensive, cytarabine and platinum-based induction treatment regimen.
